Editas Medicine, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 5, 2021 and accepted by EDGAR at Aug 5, 2021, 07:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $379.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $6.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $33.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $75.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$55.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$112.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$55.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$112.0m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$88.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $2.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $337.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $616.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $755.9m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $66.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $142.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-06-30 | $613.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-21-010390. Last ingested by Listed: Nov 10, 2026, 02:10 ET. Listed shows no prices and gives no investment advice.